ReviewTherapeutic advances in gastroenterology2014
Clostridium difficile infection: management strategies for a difficult disease.
Review in Therapeutic advances in gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.JAMA internal medicine · 2017Pooled it
- Diagnostic challenges and treatment approaches forFrontiers in microbiology · 2026Review
- Article
- Review
- Real-world Experience of Bezlotoxumab for Prevention ofOpen forum infectious diseases · 2020Article
- Article
- Cytoskeletal Tropomyosin as a Biomarker inJournal of clinical medicine research · 2019Article
- Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment.Microbiome · 2017Article
- Experience and Outcomes at a SpecializedMayo Clinic proceedings. Innovations, quality & outcomes · 2017Article
- Article
- Clostridium difficile infection: Updates in management.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2017Review
- Host response to Clostridium difficile infection: Diagnostics and detection.Journal of global antimicrobial resistance · 2016Review
- Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.Alimentary pharmacology & therapeutics · 2016Article
- Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.Internal and emergency medicine · 2016Article
- New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation.The American journal of gastroenterology · 2016Article
- Novel approaches to treating Clostridium difficile-associated colitis.Expert review of gastroenterology & hepatology · 2016Review
- Ipilimumab-associated colitis or refractory Clostridium difficile infection?BMJ case reports · 2015Article
- SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.The Journal of antimicrobial chemotherapy · 2015Article
- Predictors and outcomes of readmission for Clostridium difficile in a national sample of medicare beneficiaries.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2015Article
- Routine Treatment-ResistantCase reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremendous advancements in the field of CDI with the identification of newer risk factors, recognition of CDI in populations previously thought not at risk and development of better diagnostic modalities. Several treatment options are available for CDI apart from metronidazole and vancomycin, and include new drugs such as fidaxomicin and other options such as fecal microbiota transplantation. This review discusses the epidemiology, risk factors and outcomes from CDI, and focuses primarily on existing and evolving treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.